Somewhat Positive Media Coverage Somewhat Unlikely to Impact Concert Pharmaceuticals (CNCE) Share Price
Headlines about Concert Pharmaceuticals (NASDAQ:CNCE) have been trending somewhat positive this week, according to Accern Sentiment. Accern rates the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Concert Pharmaceuticals earned a daily sentiment score of 0.22 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 45.8093781392149 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the news headlines that may have effected Accern’s rankings:
- Aimmune Therapeutics, Inc. (AIMT) Reaches $33.38 After 4.00% Down Move; Last Week Concert Pharmaceuticals, Inc … – Hill Country Times (hillcountrytimes.com)
- Concert Pharmaceuticals to Be Added to NASDAQ Biotechnology Index (finance.yahoo.com)
- ETFs with exposure to Concert Pharmaceuticals, Inc. : December 11, 2017 (finance.yahoo.com)
- BidaskClub Upgrades Concert Pharmaceuticals (CNCE) to Strong-Buy (americanbankingnews.com)
Concert Pharmaceuticals (NASDAQ:CNCE) opened at $26.58 on Thursday. Concert Pharmaceuticals has a 52 week low of $7.11 and a 52 week high of $26.94.
In other news, insider Value Fund L. P. Biotechnology acquired 331,916 shares of Concert Pharmaceuticals stock in a transaction dated Thursday, October 19th. The stock was bought at an average cost of $15.84 per share, with a total value of $5,257,549.44. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ronald W. Barrett sold 14,156 shares of the company’s stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $24.70, for a total value of $349,653.20. Following the transaction, the director now directly owns 3,539 shares of the company’s stock, valued at $87,413.30. The disclosure for this sale can be found here. 10.10% of the stock is currently owned by insiders.
Concert Pharmaceuticals Company Profile
Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.
Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.